labetalol has been researched along with Diabetes Mellitus, Type 2 in 4 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 1 |
| Hersey, M | 1 |
| Lee, Y | 1 |
| Sharmin, S | 1 |
| Bosco, E | 1 |
| Daiello, LA | 1 |
| Shah, NR | 1 |
| Mor, V | 1 |
| Boscardin, WJ | 1 |
| Berard-Collins, CM | 1 |
| Dore, DD | 1 |
| Steinman, MA | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| ur Rehman, H | 1 |
| Ahlijah, W | 1 |
| Odugbesan, O | 1 |
| Toop, M | 1 |
| Barnett, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for labetalol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Beta-and alpha-adrenergic blockade and metabolic responses to insulin induced hypoglycaemia in diabetics.
Topics: Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Acids, Non | 1987 |
3 other studies available for labetalol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2 | 2018 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
Rumpel Leede phenomenon.
Topics: Adrenergic alpha-Antagonists; Arm; Capillaries; Depressive Disorder, Major; Diabetes Mellitus, Type | 2012 |